RNS Number: 6952 E Futura Medical PLC 05 July 2019 TR-1: S tandard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 9072 D Futura Medical PLC 28 June 2019. A second and final Price Monitoring Extension has been activated in this security. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 9061 D Futura Medical PLC 28 June 2019. The auction call period has been extended in this security by 5 minutes. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 3971 D Futura Medical PLC 25 June 2019 Director/PDMR Dealings. For further information please contact:. Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange. www.futuramedical.com.
RNS Number: 2473 D Futura Medical PLC 24 June 2019 Results of Annual General Meeting. Futura Medical plc, a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal Dermasys ® drug delivery technology currently focused on sexual health and pain, announces that at its Annual General Meeting, held earlier...
RNS Number: 0797 D Futura Medical PLC 24 June 2019 AGM Statement. Futura Medical plc, a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal Dermasys ® drug delivery technology currently focused on sexual health and pain, is pleased to announce that John Clarke, Chairman, will provide the following...
Futura Medical Plc (FUM.L) Announced the completion of patient recruitment for the first European Phase 3 study, FM57, of MED2005. The company remains on track to deliver headline data by the end of 2019. FM57 has completed recruitment of over 1,000 patients in the study for the treatment of mild, moderate and severe erectile dysfunction. The study includes approximately 60 centres across Central and Eastern Europe and will compare the efficacy of 0.2%, 0.4% and 0.6% GTN doses of MED2005 against that of placebo with an initial three-month study period for each patient.
RNS Number: 6709 C Futura Medical PLC 19 June 2019 Patient recruitment completed for MED2005 Phase 3 study. The study includes approximately 60 centres across Central and Eastern Europe and will compare the efficacy of 0.2%, 0.4% and 0.6% GTN doses of MED2005 against that of placebo with an initial three-month study period for each patient.
RNS Number: 5327 A Futura Medical PLC 30 May 2019. Futura Medical plc, a pharmaceutical company developing a portfolio of innovative products for sexual health and pain relief, makes the following update on its block listings, pursuant to AIM Rule 29 and Schedule Six of the AIM Rules for Companies. All figures relate to options over Ordinary Shares of 0.2 pence...
RNS Number: 5306 A Futura Medical PLC 30 May 2019. Notice of AGM and Annual Report. Futura Medical plc, a pharmaceutical company developing a portfolio of innovative products for sexual health and pain relief, announces that its Annual General Meeting will be held at 10 am on 24 June 2019 at the offices of Liberum at Ropemaker Place, 25 Ropemaker Street, London EC2Y 9...
RNS Number: 3860 A Futura Medical PLC 29 May 2019 TR-1: S tandard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
Futura Medical Plc (FUM.L) Announced the appointment of Liberum Capital Limited ("Liberum") as its Nominated Adviser and sole Broker, with immediate effect.
RNS Number: 9076 Z Futura Medical PLC 23 May 2019 Futura Medical. Appointment of Liberum as Nominated Adviser and Broker. Futura Medical plc, a pharmaceutical company developing a portfolio of innovative products for sexual health and pain relief, today announces the appointment, with immediate effect, of Liberum Capital Limited as its Nominated Adviser and...
RNS Number: 4016 Y Futura Medical PLC 08 May 2019. A second and final Price Monitoring Extension has been activated in this security. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 4008 Y Futura Medical PLC 08 May 2019. The auction call period has been extended in this security by 5 minutes. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 1968 Y Futura Medical PLC 07 May 2019. A second and final Price Monitoring Extension has been activated in this security. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 1959 Y Futura Medical PLC 07 May 2019. The auction call period has been extended in this security by 5 minutes. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 0749 Y Futura Medical PLC 03 May 2019. A second and final Price Monitoring Extension has been activated in this security. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 0744 Y Futura Medical PLC 03 May 2019. The auction call period has been extended in this security by 5 minutes. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
Bid
-
-
-
Ask
  • High
    -
  • OPEN
    -
  • VOL
    -
  • MKT CAP
    -m
  • LOW
    -
  • CLOSE
    -
  • AVG VOL
    -
  • SHARES IN ISSUE
    204.66M

Classification

Market Indices-

Locations

HQ
Surrey Technology Centre
40 Occam Road
Guildford
GU2 7YG
Watchlist